Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

Topical administration of neuroprotective drugs of no benefit in type 2 diabetes patients

11 Feb 2019

Topically administering the neuroprotective agents brimonidine and somatostatin does not appear to effectively prevent retinal neurodysfunction in patients with type 2 diabetes, according to a study.

The study randomized 449 patients aged between 45 and 75 years with a diabetes duration ≥5 years and an Early Treatment of Diabetic Retinopathy Study (ETDRS) level of ≤35 to receive brimonidine (n=152), somatostatin (n=145) or placebo (n=152).

Outcome investigated was the change in implicit time (IT) assessed by multifocal electroretinography between baseline and at the end of follow-up at 96 weeks. Results failed to show any neuroprotective effect of brimonidine or somatostatin.

Interestingly, in the subgroup of patients with pre-existing retinal neurodysfunction (34.7 percent), IT worsened in the placebo arm (p<0.001) but remained stable in the brimonidine and somatostatin arms.

One serious adverse event considered related to the investigational drugs was reported, namely ocular hyperaemia occurring in the brimonidine arm.

The findings indicate that while eye drops containing neuroprotective agents (brimonidine or somatostatin) are not beneficial in the primary prevention of neurodysfunction or in modulating the appearance and progression of microvascular disease in patients with type 2 diabetes, the drugs appear useful in preventing the worsening of pre-existing retinal neurodysfunction, researchers said.

It is therefore important to screen retinal neurodysfunction and identify a subset of patients in whom neuroprotective treatment might be of benefit, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.